Pictet Asset Management Holding SA Lowers Stock Holdings in Integer Holdings Co. (NYSE:ITGR)

Pictet Asset Management Holding SA decreased its position in Integer Holdings Co. (NYSE:ITGR - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,925 shares of the medical equipment provider's stock after selling 38,060 shares during the period. Pictet Asset Management Holding SA owned 0.77% of Integer worth $34,180,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Mather Group LLC. grew its stake in shares of Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in Integer during the 4th quarter valued at about $27,000. R Squared Ltd purchased a new position in Integer during the 4th quarter valued at about $44,000. Versant Capital Management Inc increased its stake in Integer by 98.4% during the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 183 shares during the period. Finally, Principal Securities Inc. increased its stake in Integer by 31.2% during the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 152 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Wall Street Analyst Weigh In

ITGR has been the subject of a number of research reports. Oppenheimer cut shares of Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Benchmark upped their price objective on Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. KeyCorp lifted their target price on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Truist Financial upped their price target on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Finally, Raymond James initiated coverage on Integer in a research note on Friday, March 28th. They issued an "outperform" rating and a $145.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $148.56.

Remove Ads

Integer Stock Down 1.9 %

Shares of ITGR traded down $2.20 during mid-day trading on Friday, reaching $113.87. The company's stock had a trading volume of 1,211,284 shares, compared to its average volume of 332,906. The company's 50 day moving average is $128.00 and its 200 day moving average is $131.69. The stock has a market cap of $3.83 billion, a PE ratio of 33.89, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Equities analysts anticipate that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.